AFM
PRVB

Anson Funds Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Anson Funds Management’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-159,337
Closed -$1.93K – 51
2019
Q2 		$1.93K Buy
+159,337
New +$867K 0.93% 12

Other funds holding PRVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Anson Funds Management's PRVB Position: Q3 2019 in Review

Anson Funds Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q3 2019, closing a stake of 159,337 shares — an estimated $1.93K sold.

Anson Funds Management first reported a position in PRVB in Q2 2019 and held it in 1 quarter. The position peaked at $1.93K in Q2 2019. 48 funds tracked by Wall St. Rank hold PRVB as of Q3 2019.

  • Anson Funds Management reported no remaining Provention Bio, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Anson Funds Management sold 159,337 Provention Bio, Inc. Common Stock shares in Q3 2019, an estimated $1.93K.
  • Anson Funds Management first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Anson Funds Management's Provention Bio, Inc. Common Stock position peaked at $1.93K in Q2 2019.
  • 48 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q3 2019.

Based on Anson Funds Management's 13F filing for Q3 2019, filed 14 Nov 2019.